TY - JOUR
T1 - Azithromycin
T2 - A promising treatment option for Mycobacterium avium complex pulmonary disease in case of intolerance to clarithromycin
AU - Oshima, Kengo
AU - Baba, Hiroaki
AU - Kanamori, Hajime
AU - Aoyagi, Tetsuji
AU - Tokuda, Koichi
AU - Kaku, Mitsuo
N1 - Funding Information:
The authors wish to thank the Honyaku Center Company for editing a draft of this manuscript.
Publisher Copyright:
© 2021 The Author(s)
PY - 2021/12
Y1 - 2021/12
N2 - Macrolide-based combination chemotherapy is recommended for the treatment of Mycobacterium avium complex (MAC) pulmonary disease (MPD). The susceptibility of the MAC to macrolide antibiotics (MAs) determines the efficacy of treatment and clinical course of MPD. However, MAs cause several adverse effects, resulting in the discontinuation of macrolide-based combination chemotherapy. We encountered two women aged 65 years and 66 years diagnosed with MPD based on bronchoscopic examinations. They were initially treated with clarithromycin-based combination chemotherapy. However, neither patient could continue with chemotherapy owing to adverse events such as rash and edema. We switched clarithromycin with azithromycin, and the patients were able to continue chemotherapy without adverse events. Both patients completed their treatment successfully. Azithromycin, which also belongs to the class of MAs, can be a promising therapeutic option for MPD in case of clarithromycin intolerance.
AB - Macrolide-based combination chemotherapy is recommended for the treatment of Mycobacterium avium complex (MAC) pulmonary disease (MPD). The susceptibility of the MAC to macrolide antibiotics (MAs) determines the efficacy of treatment and clinical course of MPD. However, MAs cause several adverse effects, resulting in the discontinuation of macrolide-based combination chemotherapy. We encountered two women aged 65 years and 66 years diagnosed with MPD based on bronchoscopic examinations. They were initially treated with clarithromycin-based combination chemotherapy. However, neither patient could continue with chemotherapy owing to adverse events such as rash and edema. We switched clarithromycin with azithromycin, and the patients were able to continue chemotherapy without adverse events. Both patients completed their treatment successfully. Azithromycin, which also belongs to the class of MAs, can be a promising therapeutic option for MPD in case of clarithromycin intolerance.
KW - Azithromycin
KW - Mycobacterium avium complex
KW - Nontuberculous mycobacterial pulmonary disease
UR - http://www.scopus.com/inward/record.url?scp=85122797372&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85122797372&partnerID=8YFLogxK
U2 - 10.1016/j.jctube.2021.100274
DO - 10.1016/j.jctube.2021.100274
M3 - Article
AN - SCOPUS:85122797372
SN - 2405-5794
VL - 25
JO - Journal of Clinical Tuberculosis and Other Mycobacterial Diseases
JF - Journal of Clinical Tuberculosis and Other Mycobacterial Diseases
M1 - 100274
ER -
